Cited by 1,249Cancer Immunotherapy and BiomarkersChromatin Remodeling and CancerRenal cell carcinoma treatment

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Open access

Miao, Diana, Margolis, Claire A., Gao, Wenhua, Voss, Martin H., Li, Wei, Martini, Dylan J., Norton, Craig, Bossé, Dominick, Wankowicz, Stephanie M., Cullen, Dana, Horak, Christine, Wind-Rotolo, Megan, Tracy, Adam, Giannakis, Marios, Hodi, Frank Stephen, Drake, Charles G., Ball, Mark W., Allaf, Mohamad E., Snyder, Alexandra, Hellmann, Matthew D., Ho, Thai, Motzer, Robert J., Signoretti, Sabina, Kaelin, William G., Choueiri, Toni K., Van Allen, Eliezer M.·2018·Science

DOI 10.1126/science.aan5951PMC PMC6035749

Open this paper in CoChat — free account

Abstract

SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.aan5951

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658

Show all 57 references

Sorted by citations

Items 501–600 of 1,001

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
Schoenfeld, D. A., Merkin, R. D., Moutafi, M. K., Martinez, S., Adeniran, A., Kumar, D., Jilaveanu, L. B., Hurwitz, M. E., Rimm, D. L., & Kluger, H. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.990367 · Cited by 19
Metabolic classifications of renal cell carcinoma reveal intrinsic connections with clinical and immune characteristics
Li, L., Chao, Z., Waikeong, U., Xiao, J., Ge, Y., Wang, Y., Xiong, Z., Ma, S., Wang, Z., Hu, Z., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03978-y · Cited by 20
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
Saliby, R. M., Zarif, T. E., Bakouny, Z., Shah, V., Xie, W., Flippot, R., Denize, T., Kane, M. H., Madsen, K. N., Ficial, M., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0996 · Cited by 19
Self-citation
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
Catalano, M., Procopio, G., Sepe, P., Santoni, M., Sessa, F., Villari, D., Nesi, G., & Roviello, G. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108499 · Cited by 20
Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance
Zheng, K. C., Hai, Y., Xi, Y., Zhang, Y., Liu, Z., Chen, W., Hu, X., Zou, X., & Hao, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04683-6 · Cited by 19
Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Li, C., Wang, Z., Yao, L., Lin, X., Jian, Y., Li, Y., Zhang, J., Shao, J., Tran, P. D., Hagman, J. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46422-5 · Cited by 22
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 20
Predicting immunotherapy response through genomics
Cormedi, M. C. V., Allen, E. M. V., & Colli, L. M. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.11.004 · Cited by 19
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis
Cantini, L., Pecci, F., Murrone, A., Tomasetti, M., Copparoni, C., Fiordoliva, I., Morgese, F., Rinaldi, S., Mazzanti, P., Rubini, C., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.024 · Cited by 18
Conjoint analysis of circulating tumor cells and solid tumors for exploring potential prognostic markers and constructing a robust novel predictive signature for breast cancer
Li, X., Sun, H., Liu, Q., Liu, Y., Hou, Y., & Jin, W. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02415-8 · Cited by 18
Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma
Schoenfeld, D. A., Zhou, R., Zairis, S., Su, W., Steinbach, N., Mathur, D., Bansal, A., Zachem, A. L., Tavarez, B., Hasson, D., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-1039 · Cited by 18
Roles of DNA damage repair and precise targeted therapy in renal cancer (Review)
Lai, Y., Li, Z., Lu, Z., Zheng, H., Chen, C., Liu, C., Yang, Y., Tang, F., & He, Z. (2022) · Oncology Reports · doi:10.3892/or.2022.8428 · Cited by 17
A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma
Luo, Y., Liu, H., Fu, H. Y., Ding, G., & Teng, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974377 · Cited by 18
Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT)
Tran, S., Plant, A., Chi, S. N., & Narendran, A. (2023) · Neuro-Oncology Practice · doi:10.1093/nop/npad005 · Cited by 18
Adaptive Immunity in Genitourinary Cancers
Koti, M., Bivalacqua, T. J., Black, P. C., Cathomen, T., Galsky, M. D., Gulley, J. L., Ingersoll, M. A., Kamat, A. M., Kassouf, W., Siemens, D. R., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.03.002 · Cited by 18
Chromatin accessibility dynamics in colorectal cancer liver metastasis: Uncovering the liver tropism at single cell resolution
Li, S., Yang, M. J., Teng, S., Lin, K., Wang, Y., Zhang, Y., Guo, W., & Wang, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106896 · Cited by 20
A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy
Yang, J., Liu, Q., & Shyr, Y. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2006 · Cited by 18
Single‐cell RNA sequencing reveals the altered innate immunity in immune checkpoint inhibitor‐related myocarditis
Lou, B., Guo, M., Zheng, T., Liu, J., Wang, C., Chen, T., Chen, F., Fan, X., Gao, S., Xiao, L., et al. (2024) · Immunology · doi:10.1111/imm.13770 · Cited by 20
High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial
Yang, X., Liao, Y., Fan, L., Lin, B., Li, J., Wu, D., Liao, D., Li, Y., Liu, J., Gao, F., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306595 · Cited by 19
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
Tunger, A., Kießler, M., Wehner, R., Temme, A., Meier, F. E., Bachmann, M. P., & Schmitz, M. (2018) · Biomedicines · doi:10.3390/biomedicines6010026 · Cited by 18
The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma
Ohsugi, H., Yoshida, T., Ohe, C., Ikeda, J., Sugi, M., Kinoshita, H., Tsuta, K., & Matsuda, T. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09075-4 · Cited by 18
Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
Lee, Y. J., Lee, J. B., Ha, S., & Kim, H. R. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0044 · Cited by 18
Aneuploidy tolerance caused by BRG1 loss allows chromosome gains and recovery of fitness
Schiavoni, F., Zuazua‐Villar, P., Roumeliotis, T. I., Benstead-Hume, G., Pardo, M., Pearl, F. M. G., Choudhary, J. S., & Downs, J. A. (2022) · Nature Communications · doi:10.1038/s41467-022-29420-3 · Cited by 18
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
Hamieh, L., Choueiri, T. K., Ogórek, B., Khabibullin, D., Rosebrock, D., Livitz, D. G., Fay, A. P., Pignon, J., McDermott, D. F., Agarwal, N., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007679 · Cited by 18
Self-citation
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation
Jin, Y., Huang, R.-J., Guan, W., Wang, Z.-Q., Mai, Z.-J., Li, Y., Xiao, J., Zhang, X., Zhao, Q., Chen, S., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01939-5 · Cited by 19
Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer
Cho, N., Kim, S.-Y., Lee, S., Park, C., Choi, S., Kim, E.-M., & Kim, K. K. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00262-7 · Cited by 18
Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma
Ferrall-Fairbanks, M. C., Chakiryan, N. H., Chobrutskiy, B. I., Kim, Y., Teer, J. K., Berglund, A., Mulé, J. J., Fournier, M., Siegel, E. M., Dhillon, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1747 · Cited by 17
Tackling drug resistance in ovarian cancer with epigenetic targeted drugs
Zhao, L., Guo, H., Chen, X., Zhang, W., He, Q., Ding, L., & Yang, B. W. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175071 · Cited by 17
mTOR Pathway Gene Mutations Predict Response to Immune Checkpoint Inhibitors in Multiple Cancers
Cheng, L., Wang, Y., Qiu, L., Chang, Y., Lu, H., Liu, C., Zhang, B., Zhou, Y., Bai, H., Xiong, L., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03436-1 · Cited by 18
ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors
Yi, Q., Pu, Y., Chao, F., Bian, P., & Lv, L. (2022) · Cancers · doi:10.3390/cancers14235951 · Cited by 17
Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy
Shi, Y., & Shin, D. S. (2023) · Biomolecules · doi:10.3390/biom13060984 · Cited by 17
An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies
PRADE, J. D. S., SOUZA, R. S. D., D’ÁVILA, C. M. D. S., SILVA, T. C. D., LIVINALLI, I. C., Bertoncelli, A. C. Z., SACCOL, F. K., Mendes, T. D. O., WENNING, L. G., Salles, T. D. R., et al. (2023) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10264 · Cited by 19
NKG2A+CD8+ T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma
Qiu, Y., Liu, L., Jiang, W., Xu, Z., Wang, J., Dai, S., Guo, J., & Xu, J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008368 · Cited by 17
Sequencing Therapies for Metastatic Renal Cell Carcinoma
Dizman, N., ARSLAN, Z. E., Feng, M. I., & Pal, S. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.008 · Cited by 17
https://cdrjournal.com/article/view/3531
Moreira, M., Pobel, C., Epaillard, N., Simonaggio, A., Oudard, S. M., & Vano, Y. A. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.16 · Cited by 20
PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes
Menasché, B. L., Davis, E. M., Wang, S., Ouyang, Y., Li, S., Yu, H., & Shen, J. (2020) · Science Advances · doi:10.1126/sciadv.abc3243 · Cited by 17
Is tumor mutational burden predictive of response to immunotherapy?Preprint
Gurjao, C., Tsukrov, D. I., Imakaev, M., Luquette, L. J., & Mirny, L. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.03.260265 · Cited by 17
Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer
Tian, M., Wang, T., & Wang, P. (2021) · Cell Transplantation · doi:10.1177/0963689720969176 · Cited by 16
CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates
Lv, Z., Feng, H., Wang, T., Li, H., & Zhang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.744107 · Cited by 16
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Hernando‐Calvo, A., Vila-Casadesús, M., Barèche, Y., González‐Medina, A., Aghababazadeh, F. A., Giacco, D. L., Martín, Á., Saavedra, O., Braña, I., Vieito, M., et al. (2023) · Med · doi:10.1016/j.medj.2023.07.006 · Cited by 17
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data
Ishihara, H., Omae, K., Nemoto, Y., Ishiyama, R., Tachibana, H., Nishimura, K., Ikeda, T., Kobari, Y., Fukuda, H., Yoshida, K., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02471-w · Cited by 16
ARID1B Deficiency Leads to Impaired DNA Damage Response and Activated cGAS-STING Pathway in Non-Small Cell Lung Cancer
Zhu, G., Liu, J., Li, Y., Huang, H., Chen, C., Wu, D., Cao, P., Su, L., Wang, Y., Zhang, H., et al. (2024) · Journal of Cancer · doi:10.7150/jca.91955 · Cited by 16
Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma
Culliford, R., Lawrence, S. E. D., Mills, C., Tippu, Z., Chubb, D., Cornish, A. J., Browning, L., Kinnersley, B., Bentham, R. B., Sud, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49692-1 · Cited by 20
The Human Pathology Atlas for deciphering the prognostic features of human cancers
Yuan, M., Zhang, C., von Feilitzen, K., Zwahlen, M., Shi, M., Li, X., Yang, H., Song, X., Türkez, H., Uhlén, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105495 · Cited by 16
Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment
Madan, R. A., & Gulley, J. L. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy145 · Cited by 16
Role of tumor gene mutations in treatment response to immune checkpoint blockades
Wang, M., Liu, Y., Wei, X., & Wei, Y. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz006 · Cited by 16
Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
Shiuan, E. F., Reddy, A., Dudzinski, S. O., Lim, A. R., Sugiura, A., Hongo, R. A., Young, K. L., Liu, X.-D., Smith, C. C., O’Neal, J. F., et al. (2021) · Cancers · doi:10.3390/cancers13061475 · Cited by 16
Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
Hou, T., Jiang, S., Wang, Y., Xie, Y., Zhang, H., Feng, Y., Ma, F., Ma, J., Liu, X., & Hu, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.608300 · Cited by 16
Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations
Principe, D. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-15714-5 · Cited by 17
Tumor mutational burden as predictive factor of response to immunotherapy
González‐Cao, M., Viteri, S., Karachaliou, N., Aguilar, A., Garcia, J. J., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.03 · Cited by 15
BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials
Liu, K., Huang, Y., Xu, Y., Wang, G., Cai, S., Zhang, X., & Shi, T. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03424-4 · Cited by 15
Improvement in neoantigen prediction via integration of RNA sequencing data for variant calling
Nguyen, B. Q. T., Tran, T. P. D., Nguyen, H. T., Nguyễn, T. N., Pham, T. M. Q., Nguyen, H. T. P., Tran, D. H., Nguyen, V. T. T., Tran, T. S., Pham, T.-V. N., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1251603 · Cited by 18
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy
Wang, S., Xiong, Y., Zhang, Y., Wang, H., Chen, M., Li, J., Luo, P., Luo, Y., Hecht, M., Frey, B., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008040 · Cited by 15
Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks
Xu, Y., Sun, X., Liu, G., Li, H., Yu, M., & Zhu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1301157 · Cited by 15
Neural regulation of drug resistance in cancer treatment
Liu, D., Li, X., Chen, X., Sun, Y. H., Tang, A., Li, Z., Zheng, J., & Shi, M. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.001 · Cited by 15
Epigenetic Heterogeneity in Human Colorectal Tumors Reveals Preferential Conservation And Evidence of Immune Surveillance
Ryser, M. D., Yu, M., Grady, W. M., Siegmund, K. D., & Shibata, D. K. (2018) · Scientific Reports · doi:10.1038/s41598-018-35621-y · Cited by 17
Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma
Adashek, J. J., Salgia, M. M., Posadas, E. M., Figlin, R. A., & Gong, J. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.004 · Cited by 15
The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy
Panian, J. A., Lin, X., Simantov, R., Derweesh, I., Choueiri, T. K., & McKay, R. R. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.03.010 · Cited by 15
Self-citation
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Fan, J., Shen, X., Wang, Y., Zhou, H., Liu, G., Li, Y., & Xu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110621 · Cited by 15
Cancer cell immune mimicry delineates onco-immunologic modulation
Gao, R., He, B., Huang, Q., Wang, Z., Yan, M., Lam, E. W. ‐., Lin, S., Wang, B., & Liu, Q. (2021) · iScience · doi:10.1016/j.isci.2021.103133 · Cited by 17
Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma
You, Z., Lv, M., He, X., Pan, Y., Ge, J., Hu, X., Zheng, Y., Huang, M., Zhou, C., & You, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871756 · Cited by 14
Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma
Sun, R., Wang, X., Chen, J., Teng, D., Chan, S., Tu, X., Wang, Z., Zuo, X., Xiang, W., Li, L., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.949110 · Cited by 15
Understanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 16
Mapping the functional network of human cancer through machine learning and pan-cancer proteogenomics
Shi, Z., Lei, J. T., Elizarraras, J. M., & Zhang, B. (2024) · Nature Cancer · doi:10.1038/s43018-024-00869-z · Cited by 16
In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice
Li, B. E., Li, G. Y., Cai, W., Zhu, Q., Seruggia, D., Fujiwara, Y., Vakoc, C. R., & Orkin, S. H. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009455 · Cited by 14
Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancer
Chou, W., Chen, W., Kuo, C., Chang, Y., Lu, Y., Li, C.-W., Hung, M., & Shen, C. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113641 · Cited by 14
Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives
Hossain, S. M., Carpenter, C., & Eccles, M. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137252 · Cited by 15
STAMBPL1/TRIM21 Balances AXL Stability Impacting Mesenchymal Phenotype and Immune Response in KIRC
Huang, S., Qin, X., Fu, S., Hu, J., Jiang, Z., Hu, M., Zhang, B., Liu, J., Chen, Y., Wang, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202405083 · Cited by 18
Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma
Gao, Y., Fan, S., Sun, X., Li, J., Dai, Y., Li, H., Ma, H., Xu, Y., & Lv, L. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07752-4 · Cited by 16
Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments
Schmidt, A. L., Siefker-Radtke, A. O., McConkey, D. J., & McGregor, B. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279905 · Cited by 14
CRISPR Screens to Identify Regulators of Tumor Immunity
LaFleur, M. W., & Sharpe, A. H. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-094725 · Cited by 16
Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review
Okano, A., Miyawaki, S., Teranishi, Y., Ohara, K., Hongo, H., Sakai, Y., Ishigami, D., Nakatomi, H., & Saito, N. (2022) · Neurologia medico-chirurgica · doi:10.2176/jns-nmc.2022-0114 · Cited by 14
Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma
Wang, J., Zhang, S., Wang, Y., Zhu, Y., Xu, X., & Guo, J. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.09.009 · Cited by 14
When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors
Yarmarkovich, M., & Maris, J. M. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.006 · Cited by 14
Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients
Gondal, M. N., Cieslik, M. P., & Chinnaiyan, A. M. (2025) · Scientific Data · doi:10.1038/s41597-025-04381-6 · Cited by 22
Role of SWI/SNF chromatin remodeling genes in lung cancer development
Monterde, B., & Varela, I. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211084 · Cited by 13
The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity
Wang, Y., Xu, J., Lan, T., Zhou, C., & Liu, P. (2023) · Cancer Medicine · doi:10.1002/cam4.6721 · Cited by 13
Defects in DNA damage responses in SWI/SNF mutant cells and their impact on immune responses
Begg, K., Braun, H., Ghaddar, N., Wu, L., & Downs, J. A. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103609 · Cited by 13
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Singla, N., Nirschl, T. R., Obradović, A., Shenderov, E., Lombardo, K. A., Liu, X., Pons, A., Zarif, J. C., Rowe, S. P., Trock, B. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51889-9 · Cited by 13
Self-citation
Research progress of SWI/SNF complex in breast cancer
Li, K., Wang, B., & Hu, H. (2024) · Epigenetics & Chromatin · doi:10.1186/s13072-024-00531-z · Cited by 14
Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study
Deng, J., Tu, S., Li, L., Li, G., & Zhang, Y. (2024) · Cancer Reports · doi:10.1002/cnr2.2116 · Cited by 15
Comprehensive analyses of nuclear mitochondria‐related genes in the molecular features, immune infiltration, and drug sensitivity of clear cell renal cell carcinoma
Zhang, Y., Cao, H., Yang, F., Wang, X., Xu, Z., Cheng, M., Yang, S., Tian, X., Zhang, N., & Xie, Y. (2024) · Medicine Advances · doi:10.1002/med4.72 · Cited by 13
The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Bao, Y., Cruz, G., Zhang, Y., Qiao, Y., Mannan, R., Hu, J., Yang, F., Gondal, M. N., Shahine, M., Kang, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0435 · Cited by 16
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity
Brodeur, M. N., Dopeso, H., Zhu, Y., Longhini, A. L. F., Gazzo, A. M., Sun, S., Koche, R. P., Qu, R., Rosenberg, L., Hamard, P.-J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk4851 · Cited by 13
Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
Fernández-Sanromán, Á., Fendler, A., Tan, B. J. Y., Cattin, A.-L., Spencer, C. E., Thompson, R. H., Au, L., Lobón, I., Pallikonda, H. A., Martin, A., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0499 · Cited by 16
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial
Goswami, S., Gao, J., Basu, S., Shapiro, D. D., Karam, J. A., Tidwell, R. S. S., Ahrar, K., Campbell, M. T., Shen, Y., Trevino, A. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57009-z · Cited by 13
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials
Martini, D. J., Liu, Y., Shabto, J. M., Lewis, C. M., Kline, M. R., Collins, H., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00736-0 · Cited by 13
Self-citation
Immune checkpoint inhibition for the treatment of renal cell carcinoma
Stühler, V., Maas, J. M., Rausch, S., Stenzl, A., & Bedke, J. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677601 · Cited by 13
Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma
Gan, C. L., Dudani, S., & Heng, D. Y. C. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000468 · Cited by 12
Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma
Meng, H., Jiang, X., Cui, J., Yin, G., Shi, B., Liu, Q., He, X., & Wang, Y. (2020) · BioMed Research International · doi:10.1155/2020/2495157 · Cited by 13
The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma
Zhou, Y., Wang, X., Zhang, W., Liu, H., Liu, D., Chen, P., Xu, D., Liu, J., Li, Y., Zeng, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.630706 · Cited by 13
Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer
Feng, Q., Song, D., Zhou, H., Lu, H., & Wang, X. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119848 · Cited by 13
Deciphering the tumour microenvironment of clear cell renal cell carcinoma: Prognostic insights from programmed death genes using machine learning
Tu, H., Hu, Q., Ma, Y., Huang, J., Luo, H., Jiang, L., Zhang, S., Jiang, C., Lai, H., Liu, J., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18524 · Cited by 13
Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
Guo, H., Li, W., Qian, L., & Cui, J. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.02.08 · Cited by 13
Self-citation
Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer
Huang, K., Hu, M., Chen, J., Wei, J., Qin, J., Lin, S., & Du, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105158 · Cited by 13
Nanotechnology-based immunotherapies to combat cancer metastasis
Zhao, Y., Bilal, M., Qindeel, M., Khan, M. I., Dhama, K., & Iqbal, H. M. N. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06660-y · Cited by 13
Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment
Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 13
Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma
Mu, Z., Dong, D. F., Sun, M., Li, L., Wei, N., & Hu, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01566 · Cited by 12
Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring
Dani, K., Rich, J. M., Kumar, S. S., Cen, H., Duddalwar, V. A., & D'souza, A. (2023) · Cancers · doi:10.3390/cancers15204934 · Cited by 12
Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy
Ma, J., Kang, Z., Yang, G., Wang, X., Si, M., Wang, Y., Li, G., Bai, S., Zeng, F., Li, M., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812334 · Cited by 12

Authors: Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., Horak, C., Wind-Rotolo, M., Tracy, A., Giannakis, M., Hodi, F. S., Drake, C. G., Ball, M. W., Allaf, M. E., Snyder, A., Hellmann, M. D., Ho, T., Motzer, R. J., Signoretti, S., Kaelin, W. G., Choueiri, T. K., & Van Allen, E. M.
Affiliations: Broad Institute (US)
Dana-Farber Cancer Institute (US)
Memorial Sloan Kettering Cancer Center (US)
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Bristol-Myers Squibb (United States) (US)
Bristol-Myers Squibb, New York, NY 10154, USA.
Columbia University Irving Medical Center (US)
Johns Hopkins University (US)
Mayo Clinic in Arizona (US)
Howard Hughes Medical Institute (US)
Corresponding author: Choueiri, Toni K.
ORCID: Miao, Diana
Margolis, Claire A.
Gao, Wenhua
Voss, Martin H.
Li, Wei
Martini, Dylan J.
Bossé, Dominick
Wind-Rotolo, Megan
Tracy, Adam
Giannakis, Marios
Hodi, Frank Stephen
Drake, Charles G.
Ball, Mark W.
Allaf, Mohamad E.
Snyder, Alexandra
Hellmann, Matthew D.
Ho, Thai
Motzer, Robert J.
Signoretti, Sabina
Kaelin, William G.
Choueiri, Toni K.
Van Allen, Eliezer M.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2018-02-16
Volume: 359
Issue: 6377
Pages: 801-806
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.aan5951
PMC: PMC6035749
OpenAlex: W2782183686
Cited by: 1,249
References: 57
Citations by year: 2026: 73 · 2025: 93 · 2024: 153 · 2023: 164 · 2022: 186 · 2021: 195 · 2020: 179 · 2019: 113 · 2018: 89
FWCI: 54.48
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (K08 CA188615, U24CA224316)
Howard Hughes Medical Institute (Medical Research Fellowship)
American Association for Cancer Research (KureIt Grant for Kidney Research)
NIH Office of the Director (P30 CA008748)
Bristol-Myers Squibb (II-ON Consortium)
Dana-Farber Cancer Institute (Loker Pinard Funds for Kidney Cancer Research)
Dana-Farber/Harvard Cancer Center (Kidney SPORE)
BroadNext10
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: clear cell renal cell carcinoma, immune checkpoint inhibitors, SWI/SNF complex, PBRM1 mutation, tumor response prediction, antitumor immunity, interferon-gamma, T cell-mediated killing, metastatic renal cell carcinoma, cancer genomics
MeSH terms: Carcinoma, Renal Cell, Chromosomal Proteins, Non-Histone, Humans, Immunotherapy, Kidney Neoplasms, Mutation, Transcription Factors, Cohort Studies, Gene Expression Profiling, Genomics, Exome, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks